Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | DNM2 | P50570 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782194 | 0.84 | KDM4E (0.57) | KDM4EHTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL1783191 | 0.82 | ABL1 (0.47) | ABL1SMN1; SMN2KCNH3S1PR2LMNA | |
| SCHEMBL28363772 | 0.82 | NPC1 (0.52) | ABL1MAPTMEN1KMT2APOLB | |
| SCHEMBL11193185 | 0.80 | HDAC6 (0.47) | ABL1KDM4EMEN1KMT2AKCNH3 | |
| SCHEMBL14035880 | 0.79 | KDM4E (0.50) | KDM4EADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL8214084 | 0.79 | ABL1 (0.53) | ABL1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL8212647 | 0.79 | ABL1 (0.53) | ABL1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL8216585 | 0.79 | ABL1 (0.53) | ABL1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL1784168 | 0.79 | ABL1 (0.44) | ABL1HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL11498100 | 0.76 | ABL1 (0.59) | ABL1MAPTKCNH3ALDH1A1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445511-B2 | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases | Centre National de la Recherche Scientifique (SNRS) (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HCRTR2, HCRTR1, CHRNA2 | ABL1 3272/4885KDM4E 4678/4885HTR1A 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.